Vitiligo Trial, Recruiting NCT06900777 Sponsor: Xijing Hospital Condition: Vitiligo
Back to Vitiligo

Vitiligo Trial, Recruiting

NCT06900777
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Children between 4 and 12 years old who have been diagnosed with a fast-spreading type of vitiligo (called non-segmental vitiligo) that has been getting worse in the past 6 weeks
  • Children whose vitiligo affects between 1% and 50% of their total body skin
  • Children whose parent or legal guardian agrees to take part and signs a consent form

Who may not be able to join:

  • Children whose vitiligo has been stable and is not currently spreading
  • Children with certain other types of vitiligo, including segmental, mucosal, undetermined, or generalized vitiligo
  • Children who have taken medicines that suppress the immune system in the past 4 weeks
  • Children who are known to be allergic to tacrolimus, related drugs (called macrolides), or any ingredients in the study medication
  • Children with serious health conditions affecting the liver or kidneys that would make taking the study medicine unsafe
  • Children who are obese or have certain other health conditions, such as tuberculosis, active or ongoing infections, high blood pressure, or a heart condition they were born with
  • Children whose doctors feel that taking part in the trial could put them at risk or affect how the trial runs (confirm with trial site)

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Zhe Jian, Associate Professor, First Affiliated Hospital of Air Force Medical University

Phone: +862984775406

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Xijing Hospital
Registry
ClinicalTrials.gov
Start date
1 April 2025
Est. completion
1 April 2026

Where this trial is recruiting

🇨🇳 China

Primary endpoints

Percentage of Participants Achieving VASI 50 Response

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov